Navigation Links
Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
Date:3/4/2009

100% Technical Success, No Peri-procedural Complications Reported With Coronary Device

DOYLESTOWN, Pa., March 4 /PRNewswire/ -- Prescient Medical, Inc. reached a crucial milestone in February by completing the enrollment of 30 patients in the first phase of its first-in-human clinical trial for the vProtect(TM) Luminal Shield, conducted at the Corbic Research Institute in Colombia. The Shield successfully crossed all target lesions and was safely implanted in all 30 patients, with a technical success rate of 100%. No procedural or in-hospital complications were reported for any of the patients. The patients enrolled in the study had non-calcified lesions in coronary arteries, lesions that would normally be treated with traditional balloon-expandable stents.

No major adverse coronary events (MACE) were reported at 30 days post-implant in the 28 patients who had reached that milestone. Nine-month angiographic follow-up was reported for 2 initial patients; there was no evidence of significant neointimal growth in these patients. "We are very pleased with the performance of the Shield in this preliminary study. We have achieved an excellent technical result, and soon we will know more about clinical outcomes with the Shield," said co-principal investigator Juan A. Delgado, MD of Corbic Research Institute.

Prescient Medical has also broken new ground with a study evaluating use of the vProtect(TM) Luminal Shield in non-obstructive "vulnerable plaque" lesions that may rupture and cause acute myocardial infarction. According to Dr. Delgado, "The self-expanding Shield is designed to deploy with less injury to the artery, which should reduce neointimal overgrowth compared with currently marketed bare metal stents. We think these properties make the Shield a promising treatment to stabilize vulnerable plaque and prevent major events like heart attacks."

About Prescient Medical, Inc.

Prescient Medical, Inc. is a privately held medical device company dedicated to reducing deaths from heart attacks, the leading cause of death in much of the world. For more information, please visit our website at www.prescientmedical.com or call +1-866-376-0500.


'/>"/>
SOURCE Prescient Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
2. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
3. Impact Medical Solutions Announces Initiation of Pilot Clinical Trial and Listing on Frankfurt Stock Exchange
4. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
5. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
6. Foreign Medical Devices are in High Demand in Russia
7. Oridion Announces Significant Medical Studies Presented at STA
8. AGA Medical Corporation Launches Web-Based Stroke Education and Awareness Program Featuring Professional Football Player Tedy Bruschi
9. Impact Medical Solutions Announces Appointment of New Director and Corporate Update
10. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
11. ProUroCare Medical Inc. Announces Pricing of Equity Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...  In a startling report released today, National Safety Council ... a comprehensive, proven plan to eliminate prescription opioid overdoses. ... states are tackling the worst drug crisis in recorded U.S. history, ... Kentucky , New Mexico , ... the 28 failing states, three – Michigan , ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the ... affiliation with Tennessee Counseling Association. This new relationship allows TherapySites to ... Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their ... Eyeglasses . , Millions of individuals in the United States and Canada wear eyeglasses. ... way to both correct vision and make a fashion statement. Even celebrities use glasses ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
Breaking Medicine News(10 mins):